Decreased in vitro anticoagulant potency of Rivaroxaban and Apixaban in plasma from patients with cirrhosis

E-ISSN： 1527-3350|61|4|1435-1436

ISSN： 0270-9139

Source： HEPATOLOGY, Vol.61, Iss.4, 2015-04, pp. : 1435-1436

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Amylin fasting plasma levels are decreased in patients with osteoporosis

By Bronský J. Průša R.

Osteoporosis International, Vol. 15, Iss. 3, 2004-03 ,pp. : 243-247

Springer Publishing Company

Access to resources Recommend Favorite

Efficacy and safety of the anticoagulant drug, danaparoid sodium, in the treatment of portal vein thrombosis in patients with liver cirrhosis

HEPATOLOGY RESEARCH, Vol. 45, Iss. 6, 2015-06 ,pp. : 656-662

John Wiley & Sons Inc

Access to resources Recommend Favorite

Might apixaban be the optimal oral anticoagulant for haemophiliacs with atrial fibrillation?

HAEMOPHILIA, Vol. 21, Iss. 4, 2015-07 ,pp. : e338-e340

John Wiley & Sons Inc

Access to resources Recommend Favorite

Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Vol. 13, Iss. 12, 2015-12 ,pp. : 2187-2191

John Wiley & Sons Inc

Access to resources Recommend Favorite

Plasma cystatin C as a marker of renal function in patients with liver cirrhosis

By Randers E. Ivarsen P. Erlandsen E. J. Hansen E. F. Aagaard N. K. Bendtsen F. Vilstrup H.

Scandinavian Journal of Clinical and Laboratory Investigation, Vol. 62, Iss. 2, 2002-04 ,pp. : 129-134

Informa Healthcare

Access to resources Recommend Favorite